Abciximab Recombinant Human Monoclonal Antibody, Invitrogen™

Description

• Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles
• Store at 2 to 8 °C for one week
• Store at -20 to -80 °C for twelve months from the date of receipt
• Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3
• Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules
• It also binds to vitronectin (alpha-v-beta-3) receptor found on platelets and vessel wall endothelial and smooth muscle cells
• Abciximab binds to the intact platelet GpiIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation
• This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GpiIb/IIIa
• By binding to the vitronectin receptor (also known as the alpha-v-beta-3 integrin), abciximab blocks effects mediated by this integrin which include cell adhesion
• Furthermore, abciximab blocks Mac-1 receptor on monocytes and neutrophils thus inhibiting monocyte adhesion.